Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Prevention of Toxicity in HSCT
NCT06449625Phase 2Not yet recruiting
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in gastrointestinal mucositis comparing Semaglutide with Placebo (2 arms). Primary endpoint: Gastrointestinal mucositis severity. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
03
Conditions
gastrointestinal mucositis
Beyond the preview
Go deeper on NCT06449625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06449625.